http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.
Preface -- Clinical instruments to evaluate and guide treatment in schizophrenia -- Cognitive deficits in schizophrenia- Muscarinic mechanisms in psychotic disorders -- Nicotinic mechanisms in psychotic disorders -- GABAergic circuits in schizophrenia: targets for new treatments in schizophrenia -- Inhibitors of glycine transport as potential new treatments in schizophrenia -- The role of glutamate in schizophrenia -- Metabotropic glutamate receptors as targets for new treatments in schizophrenia -- 5-HT2C agonism as a principle for new treatments in schizophrenia.- The role of dopamine D3 receptors for antipsychotic activity and cognitive functions -- Phosphodiesterase inhibitors as potential new treatments in schizophrenia -- Disease modifying approaches to schizophrenia -- A novel therapeutic strategy: medication-enhancement of cognitive therapies in schizophrenia -- Transgenic animals reflecting aspects of schizophrenia -- Behavioral animal models of pro-cognitive treatments for schizophrenia. .
Handbook of Experimental Pharmacology, 213